Neuropathy and pain after breast cancer treatment: a prospective observational study
- PMID: 35636394
- DOI: 10.1515/sjpain-2022-0017
Neuropathy and pain after breast cancer treatment: a prospective observational study
Abstract
Objectives: Neurological complications including pain are common after treatment for breast cancer. This prospective study investigated the symptoms, intensity and interference of chemotherapy-induced peripheral neuro-pathy. (CIPN) in the feet and hands compared to surgery- and radiation-induced neuropathy in the breast and upper arm.
Methods: Consecutive patients referred to surgery for breast cancer were included in a prospective study and completed a questionnaire at baseline and a follow-up questionnaire and interview after one year. CIPN was assessed with the CIPN20 questionnaire and the Michigan Neuropathy Screening Instrument questionnaire (MNSIq). Pain intensity was rated on a numeric rating scale (NRS, 0-10).
Results: In total 144 patients were included, of which 73 received chemotherapy. At one-year follow-up, symptoms of polyneuropathy were more common in patients treated with chemotherapy. Tingling or numbness in the feet in those treated/not treated with chemotherapy was reported by 44 (62%) and 15 (21%), respectively. Pain was present in 22 (30%) and 10 (14%), respectively. Pain in the area of surgery was reported by 66 (46%). Although less common, pain in the feet in those treated with chemotherapy was rated as more intense and with more daily life interference than pain in the surgical area (NRS 5.5 (SD 1.9) vs. 3.1 (SD 1.9).
Conclusions: Neurological complications including pain following surgery and chemotherapy represent a burden to breast cancer survivors. In those who had received chemotherapy, pain in the feet was less common than pain in the surgical area, but pain in the feet was more intense and had a higher interference with daily life. Our study emphasizes the need for either baseline data or a control population for improved estimation of the presence and severity of CIPN and pain from questionnaires.
Keywords: CIPN; breast cancer; chemotherapy; lumpectomy; mastectomy; polyneuropathy.
© 2022 Kristine Bennedsgaard et al., published by De Gruyter, Berlin/Boston.
References
-
- Kaufmann, M, von Minckwitz, G, Mamounas, EP, Cameron, D, Carey, LA, Cristofanilli, M, et al.. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012;19:1508–16. https://doi.org/10.1245/s10434-011-2108-2 . - DOI
-
- Cavaletti, G, Alberti, P, Argyriou, AA, Lustberg, M, Staff, NP, Tamburin, S. Chemotherapy-induced peripheral neurotoxicity: a multifaceted, still unsolved issue. J Peripher Nerv Syst: JPNS 2019;24:S6–12. https://doi.org/10.1111/jns.12337 . - DOI
-
- Bennedsgaard, K, Ventzel, L, Andersen, NT, Themistocleous, AC, Bennett, DL, Jensen, TS, et al.. Oxaliplatin- and docetaxel-induced polyneuropathy: clinical and neurophysiological characteristics. J Peripher Nerv Syst: JPNS 2020;25:377–87. https://doi.org/10.1111/jns.12413 . - DOI
-
- Bennedsgaard, K, Ventzel, L, Themistocleous, AC, Bennett, DL, Jensen, AB, Jensen, AR, et al.. Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy. Cancer Med 2020;9:5114–23. https://doi.org/10.1002/cam4.3129 . - DOI
-
- Hershman, DL, Weimer, LH, Wang, A, Kranwinkel, G, Brafman, L, Fuentes, D, et al.. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011;125:767–74. https://doi.org/10.1007/s10549-010-1278-0 . - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical